Abbott reaches agreements to resolve a portion of litigation involving its specialty formulas for preterm infants

Abbott reaches agreements to resolve a portion of litigation involving its specialty formulas for preterm infants

* Agreements will resolve the Gill case and claims involving approximately 2,000 other individuals * Abbott and the medical community stand by the safety of preterm infant formulas * Regulators and medical professionals recognize that these products are safe and necessary, and there is no reliable scientific evidence that they cause necrotizing enterocolitis ABBOTT PARK, Ill., Aug. 20, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) has reached agreements with three law firms to resolve the Gill case and claims involving approximately 2,000 other individuals relating to the company's specialty formulas for preterm infants.